Trial result ·
Consolidation Therapy of Probiotics With Rifaximin Prevent Relapse in Rifaximin-Responsive Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Randomized Clinical Trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at people with IBS-D, a bowel problem with diarrhea. All of them had first done well on rifaximin taken for 2 weeks. They were then put into groups by chance, at several centers. One group took Medilac-S capsules with live gut bacteria for 4 weeks. The other group got no more treatment. The people and doctors knew which group each person was in. The main goal was to see how many people had their symptoms come back.
What they found
In all, 143 people took part. Symptoms came back in 38 of 95 people in the Medilac-S group. In the group with no more treatment, they came back in 28 of 48. The authors say this gap was significant. The Medilac-S group also had fewer bowel movements. Their stools were also less loose. People whose symptoms came back had more of some gut bacteria. These included Faecalibacterium and Streptococcus.
What it means for patients
The authors conclude that Medilac-S after rifaximin helped keep IBS-D calm for a long time. They say it helped in particular with how often people went. It also helped with how loose the stools were. They also say it helped stop symptoms from coming back.
Why it is not certain yet
The people and doctors knew who got the capsules. This kind of open design can sway results. Only people who first did well on rifaximin took part. The abstract does not say how long people were followed. It also gives no results on side effects.
Source
Consolidation Therapy of Probiotics With Rifaximin Prevent Relapse in Rifaximin-Responsive Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Randomized Clinical Trial.
PubMed · PMID 42609157We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Irritable bowel syndrome publications